Search details
1.
Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.
Cell
; 166(4): 1041-1054, 2016 Aug 11.
Article
in English
| MEDLINE | ID: mdl-27499020
2.
Massively parallel, computationally guided design of a proenzyme.
Proc Natl Acad Sci U S A
; 119(15): e2116097119, 2022 04 12.
Article
in English
| MEDLINE | ID: mdl-35377786
3.
Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression.
Genes Dev
; 31(16): 1641-1654, 2017 08 15.
Article
in English
| MEDLINE | ID: mdl-28947497
4.
Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade.
Genes Dev
; 31(20): 2067-2084, 2017 10 15.
Article
in English
| MEDLINE | ID: mdl-29138276
5.
Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via ß-catenin signaling.
Genes Dev
; 26(20): 2271-85, 2012 Oct 15.
Article
in English
| MEDLINE | ID: mdl-23070813
6.
Functional screen identifies kinases driving prostate cancer visceral and bone metastasis.
Proc Natl Acad Sci U S A
; 113(2): E172-81, 2016 Jan 12.
Article
in English
| MEDLINE | ID: mdl-26621741
7.
Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.
Proc Natl Acad Sci U S A
; 113(42): E6457-E6466, 2016 10 18.
Article
in English
| MEDLINE | ID: mdl-27694579
8.
Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.
Proc Natl Acad Sci U S A
; 110(50): 20111-6, 2013 Dec 10.
Article
in English
| MEDLINE | ID: mdl-24282295
9.
Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.
Proc Natl Acad Sci U S A
; 110(49): E4762-9, 2013 Dec 03.
Article
in English
| MEDLINE | ID: mdl-24248375
10.
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.
Proc Natl Acad Sci U S A
; 109(5): 1643-8, 2012 Jan 31.
Article
in English
| MEDLINE | ID: mdl-22307624
11.
Dissemination of Circulating Tumor Cells in Breast and Prostate Cancer: Implications for Early Detection.
Endocrinology
; 165(4)2024 Feb 20.
Article
in English
| MEDLINE | ID: mdl-38366552
12.
Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.
Mol Cancer Res
; 22(5): 452-464, 2024 May 02.
Article
in English
| MEDLINE | ID: mdl-38345532
13.
Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity.
Cancer Res
; 84(5): 703-724, 2024 03 04.
Article
in English
| MEDLINE | ID: mdl-38038968
14.
Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancer.
bioRxiv
; 2023 Apr 25.
Article
in English
| MEDLINE | ID: mdl-37163118
15.
Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC.
Front Oncol
; 13: 1210487, 2023.
Article
in English
| MEDLINE | ID: mdl-37456235
16.
ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer.
Front Endocrinol (Lausanne)
; 14: 1093332, 2023.
Article
in English
| MEDLINE | ID: mdl-37065756
17.
Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells.
Cancer Res Commun
; 3(4): 592-606, 2023 04.
Article
in English
| MEDLINE | ID: mdl-37077937
18.
Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.
bioRxiv
; 2023 Aug 05.
Article
in English
| MEDLINE | ID: mdl-37577653
19.
ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems.
Commun Biol
; 6(1): 417, 2023 04 14.
Article
in English
| MEDLINE | ID: mdl-37059746
20.
PIP5K1α inhibition as a therapeutic strategy for prostate cancer.
Proc Natl Acad Sci U S A
; 111(35): 12578-9, 2014 Sep 02.
Article
in English
| MEDLINE | ID: mdl-25118275